Search results for "hipercolesterolemia"

showing 9 items of 9 documents

Study of the systemic inflammation associated to primary hypercholesterolemia, its modulation and its impact in atherosclerosis. Role of CXCL16/CXCR6…

2019

La hipercolesterolemia primaria (HP) es un desorden metabólico caracterizado por unos elevados niveles circulantes de lipoproteínas de baja densidad (LDL), así como por una inflamación sistémica de bajo grado, que puede finalmente dar lugar al desarrollo de aterosclerosis. Debido a la escasa información que se tiene de la enfermedad a nivel inmunológico, hemos caracterizado el comportamiento de diferentes mediadores solubles y celulares de la inflamación y sus posibles consecuencias. Para ello se ha empleado sangre completa de 22 pacientes con HP y 21 controles de semejante edad. En todos ellos se ha analizado la sangre por citometría de flujo para determinar la activación leucocitaria y pl…

:CIENCIAS MÉDICAS ::Patología::Patología cardiovascular [UNESCO]:CIENCIAS DE LA VIDA::Inmunología [UNESCO]aterosclerosisUNESCO::CIENCIAS MÉDICAS ::Patología::Patología cardiovascular:CIENCIAS MÉDICAS ::Farmacología [UNESCO]UNESCO::CIENCIAS DE LA VIDA::InmunologíahipercolesterolemiaUNESCO::CIENCIAS MÉDICAS ::Farmacologíaaneurisma
researchProduct

Familial hypercholesterolæmia in children and adolescents: Gaining decades of life by optimizing detection and treatment

2015

Contains fulltext : 155263.pdf (Publisher’s version ) (Open Access) Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to improve awareness of the need for early detection and management of FH children. Familial hypercholesterolaemia is diagnosed either on phenotypic criteria, i.e. an elevated low-density lipoprotein cholesterol (LDL-C) level plus a family history of elevated LDL-C, premature coronary artery disease and/or genetic diagnosis, or positive genetic testin…

CounselingEuropean Atherosclerosis Society Consensus PanelPediatricsCardiac & Cardiovascular SystemsSTATIN THERAPYSettore MED/09 - Medicina InternaVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Familial hypercholesterolemiaAdolescentsCarotid Intima-Media ThicknessINTIMA-MEDIA THICKNESSCost of IllnessPregnancyRisk FactorsDiagnosisYOUNG-ADULTSHIPERCOLESTEROLEMIA (DIAGNÓSTICO;TERAPIA;TENDÊNCIAS)Family historyYoung adultChildChildrenEvidence-Based Medicinemedicine.diagnostic_testHomozygoteMiddle AgedFamilial hypercholesterolæmia3. Good healthEconomics MedicalAdolescents; Children; Consensus statement; Diagnosis; Ezetimibe; Familial hypercholesterolæmia; LDL cholesterol; PCSK9 inhibitor; Statin; Treatment; Cardiology and Cardiovascular MedicineCARDIOVASCULAR-DISEASEConsensus statementLDL cholesterolFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & BiomedicineDiagnosimedicine.drugAdultHeterozygotemedicine.medical_specialtyStatinAdolescentmedicine.drug_classPCSK9 inhibitorENDOTHELIAL FUNCTIONLOW-DENSITY-LIPOPROTEINReviewsCOST-EFFECTIVENESS ANALYSIS1102 Cardiovascular Medicine And HaematologyMedication AdherenceHyperlipoproteinemia Type IIYoung AdultLife ExpectancyEzetimibemedicineHumansCORONARY-HEART-DISEASEGenetic TestingGenetic testingPregnancyScience & TechnologyClinical Laboratory Techniquesbusiness.industryPreventionStatinAtherosclerosismedicine.diseaseEzetimibeDietASSOCIATION EXPERT PANELBLOOD-PRESSURE RESEARCHPregnancy ComplicationsTreatmentEarly DiagnosisIntima-media thicknessCardiovascular System & HematologyDietary SupplementsPhysical therapyCardiovascular System & Cardiologybusiness
researchProduct

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper fr…

2014

Item does not contain fulltext AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH. METHODS AND RESULTS: Early diagn…

Homozygous Familial HypercholesterolemiaSettore MED/09 - Medicina InternaVascular damage Radboud Institute for Health Sciences [Radboudumc 16]MipomersenLipoprotein apheresisGene FrequencyDiagnosisconsensuMedicineChildPhenotypic heterogeneityCiències de la salutAnticholesteremic AgentsHomozygoteCiencias de la saludPedigree3. Good healthEuropePhenotypeCardiovascular DiseasesPractice Guidelines as TopicBlood Component Removallipids (amino acids peptides and proteins)HipercolesterolèmiaHIPERCOLESTEROLEMIA (DIAGNÓSTICO)Cardiology and Cardiovascular MedicineLipoprotein apheresismedicine.medical_specialtyConsensusClinical UpdateEvinacumabReviewsguide line1102 Cardiovascular Medicine And Haematology1016-5169Diagnosis DifferentialHyperlipoproteinemia Type IIGenetic HeterogeneityArcus SenilisHomozygous familial hypercholesterolaemiaGeneticsXanthomatosisHumansGynecologybusiness.industryStatinsHealth sciencesCholesterol LDLAtherosclerosisEzetimibeLomitapideLiver TransplantationEarly DiagnosisCardiovascular System & HematologyHomozygous familial hypercholesterolaemia; consensus; guide lineMutationEuropean atherosclerosis societybusinessAterosclerosiEuropean Heart Journal
researchProduct

Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019

2019

Resumen Un grupo de expertos convocado por la Sociedad Espanola de Arteriosclerosis (SEA) se ha encargado de actualizar el documento de la SEA sobre las indicaciones de los inhibidores de PCSK9 (iPCSK9) en la practica clinica publicadas en 2016. Esta actualizacion es necesaria porque en el periodo transcurrido hasta la actualidad se han publicado los resultados de los ensayos clinicos realizados a gran escala con iPCSK9 que demuestran que, ademas de su alta potencia para disminuir el colesterol aterogenico, disminuyen el riesgo de presentar episodios de enfermedad cardiovascular aterosclerotica en los pacientes con enfermedad tanto estable como reciente, y con un alto grado de seguridad. La…

Inhibidores de la proproteína convertasa subtilisina kexina 9ArteriosclerosisEnfermedad cardiovascularFamilial hypercholesterolemiaClinical indicationsLow density lipoprotein030204 cardiovascular system & hematologyArteriosclerosi03 medical and health sciencesLipoproteínas de baja densidad0302 clinical medicineIndicaciones clínicasTratamientoPharmacology (medical)030212 general & internal medicineConsensus documentHipercolesterolemia familiarNumber needed to treatCardiovascular diseaseDocumento de consensoTreatmentArterioesclerosiCholesterolProprotein convertase subtilisin kexin 9 inhibitorsCardiology and Cardiovascular MedicineColesterolNúmero necesario a tratar
researchProduct

Efecto de la sobrecarga oral con grasa insaturada sobre los marcadores de estrés oxidativo e inflamación : estudios de lipemia postprandial en sujeto…

2011

Objetivos: Estudiar el efecto en los marcadores de estrés oxidativo (EO) en linfomonocitos circulantes y de inflamación sistémica relacionada con la arteriosclerosis tras un sobrecarga oral con grasa (SOG) monoinsaturada en sujetos con hipercolesterolemia familiar (HF) heterocigota y comparar esta respuesta con la obtenida en sujetos normolipémicos normoglucémicos. Sujetos y métodos: Se estudiaron 14 pacientes FH y 22 voluntarios sanos como grupo control. En ambos, se determinaron el cociente glutation oxidado/reducido y niveles de malondialdehido en linfomonocitos y niveles plasmáticos de IL-6, IL8, TNFα, eotaxina, MCP-1 y MIP-1α en ayunas y a las 2, 4, 6 y 8 horas tras una SOG. Asimismo, …

Lipemia postprandialHipercolesterolemia familiar heterocigotaEstrés oxidativo:CIENCIAS MÉDICAS ::Medicina interna::Endocrinología [UNESCO]UNESCO::CIENCIAS MÉDICAS ::Medicina interna::Endocrinología
researchProduct

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

2016

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the receptor along with LDL and targeting it for lysosomal destruction. PCSK9 also enhances the degradation of very-low-density-lipoprotein receptor (VLDLR) and lipoprotein receptor-related protein 1 (LRP-1) in a LDL-receptor independent manner. This role in lipid homeostasis presents PCSK9 as an attractive target for the therapeutic management of familial hypercholesterolemia as well as other refractory dyslipidaemias. However, PCSK9 mediates multifarious functions independent of its role in lipid homeostasis, which can be…

Male0301 basic medicineCell signalingHIPERCOLESTEROLEMIALow-density lipoprotein receptor gene familyHypercholesterolemiaMice TransgenicFamilial hypercholesterolemiaBiologyAntiviral AgentsPermeabilityMice03 medical and health sciencesAlzheimer DiseasemedicineAnimalsHomeostasisHumansGlucose homeostasisRNA Small InterferingEpithelial Sodium ChannelsGlycoproteinsNeuronsPCSK9PCSK9 InhibitorsAntibodies MonoclonalCell DifferentiationOligonucleotides Antisensemedicine.diseaseProprotein convertaseLipidsCircadian RhythmLiver RegenerationCell biology030104 developmental biologyReceptors LDLBiochemistryLDL receptorKexinFemalelipids (amino acids peptides and proteins)CRISPR-Cas SystemsProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Repositioning of the global epicentre of non-optimal cholesterol

2020

Publisher's version (útgefin grein)

MaleMyocardial Ischemia/bloodBLOOD-PRESSUREtriglicéridos0302 clinical medicineCardiovascular diseases ; Risk factorsHDL cholesterol80 and overCARDIOVASCULAR RISK-FACTORSPublic health surveillance//purl.org/pe-repo/ocde/ford#3.02.04 [https]BlóðrásarsjúkdómarSocioeconomicsmediana edadComputingMilieux_MISCELLANEOUSPOPULATIONHypercholesterolemia/bloodAged 80 and overCholesterol HDL/bloodancianoeducation.field_of_studyKólesterólriskitekijätadulto3. Good healthadulto jovenTriglycerides/bloodCardiovascular diseasesGeographyCholesterolManchester Institute for Collaborative Research on AgeingCholesterol LDL/bloodDENSITY-LIPOPROTEIN CHOLESTEROLEndokrinologi och diabetesNCD Risk Factor Collaboration (NCD-RisC)Science & Technology - Other Topics//purl.org/becyt/ford/3 [https]Westernteorema de Bayesmedicine.medical_specialtyResearchInstitutes_Networks_Beacons/MICRAHDLMedicinaHypercholesterolemiahipercolesterolemiaNursingHEART-DISEASEEndocrinology and DiabetesHigh blood cholesterol.HDL-kolesteroliArticleLDLravintoHealth risk assessment03 medical and health sciences//purl.org/becyt/ford/3.3 [https]SDG 3 - Good Health and Well-beingBlood cholesterolHumanseducationSERUM-CHOLESTEROLVLAGAgedScience & TechnologyCholesterolPublic healthOmvårdnadHuman healthVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710Bayes TheoremATHEROSCLEROSIS SOCIETYRisk factorschemistryLipid-lowering medicationsFaculdade de Ciências SociaisEast and southeast Asiaalueelliset erotInternationalityNutrition and Disease[SDV]Life Sciences [q-bio]kolesterolihumanosMyocardial IschemiaMedizinadolescenteNon-HDL cholesterolBlood lipids030204 cardiovascular system & hematologyisquemia miocárdicachemistry.chemical_compoundCholesterol epidemiologyMEDICATION USEVoeding en ZiekteMedicine and Health SciencesAdolescent; Adult; Aged; Aged 80 and over; Bayes Theorem; Cholesterol HDL; Cholesterol LDL; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Stroke; Triglycerides; Young Adult; Internationality030212 general & internal medicine2. Zero hungerMultidisciplinaryMortality rateRepositioningStroke/blood1. No povertyPublic Health Global Health Social Medicine and EpidemiologycolesterolMiddle AgedVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 7103142 Public health care science environmental and occupational healthPeer reviewStrokeMultidisciplinary SciencesTrend analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalelipids (amino acids peptides and proteins)LIPIDSAdultAdolescentGeneral Science & TechnologyPopulationepicentre20-YEAR TRENDSYoung AdultmedicineLife Scienceddc:610accidente cerebrovascularDisease burdenTriglyceridesNutritionHigh density lipoproteinsnon-optimal cholesterolCholesterol HDLinternacionalidadCholesterol LDLTreatmentFolkhälsovetenskap global hälsa socialmedicin och epidemiologi
researchProduct

Influencia de la situación postprandial sobre el eje CCL11/CCR3 en sujetos con hipercolesterolemia

2020

Introducción: La enfermedad cardiovascular es la principal causa de morbilidad y mortalidad a nivel mundial y su base patogénica es la arteriosclerosis (AE). La hipercolesterolemia primaria es uno de los factores de riesgo más importantes para la AE y este proceso está asociado a cierto grado de inflamación sistémica, habiéndose descrito en la actualidad varias citoquinas quimiotácticas involucradas en el proceso arteriosclerótico. Se ha detectado la influencia de la eotaxina-1 (CCL11) y de su receptor, CCR3, en la aparición y desarrollo de la arteriosclerosis, así como la influencia de la lipemia postprandial (LPP) como factor de riesgo independiente de enfermedad cardiovascular, aunque no…

inflamaciónUNESCO::CIENCIAS MÉDICASeotaxinapostprandialhipercolesterolemiaCCR3:CIENCIAS MÉDICAS [UNESCO]CCL11
researchProduct

Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la…

2015

Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening disease characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) has recently published a clinical guide to diagnose and manage HoFH (Eur Heart J. 2014;35:2146-57). Both the Spanish Society of Atherosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF) consider this European Consensus document of great value and utility. However, there are particularities in our country which advise to ha…

medicine.medical_specialtyEzetimibeHomozygous familial hypercholesterolaemiaDiagnosisMedicinePharmacology (medical)Lipoprotein cholesterolNational healthEzetimibabusiness.industryAtherosclerotic cardiovascular diseaseDiagnósticoAféresisStatinsHipercolesterolemia familiar homocigotaLomitapidaEzetimibeLomitapidePatient managementLDL apheresisFamily medicineEuropean atherosclerosis societylipids (amino acids peptides and proteins)ApheresisCardiology and Cardiovascular MedicinebusinessEstatinasmedicine.drug
researchProduct